ATE272115T1 - Polypeptide die unnatürliche signalmotive enthalten - Google Patents
Polypeptide die unnatürliche signalmotive enthaltenInfo
- Publication number
- ATE272115T1 ATE272115T1 AT00972995T AT00972995T ATE272115T1 AT E272115 T1 ATE272115 T1 AT E272115T1 AT 00972995 T AT00972995 T AT 00972995T AT 00972995 T AT00972995 T AT 00972995T AT E272115 T1 ATE272115 T1 AT E272115T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptides
- motifs
- contain
- contain unnatural
- motives
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 108700010039 chimeric receptor Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9925848.5A GB9925848D0 (en) | 1999-11-01 | 1999-11-01 | Biological products |
| PCT/GB2000/004183 WO2001032709A2 (en) | 1999-11-01 | 2000-11-01 | Polypeptides with non-natural primary signalling motifs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE272115T1 true ATE272115T1 (de) | 2004-08-15 |
Family
ID=10863765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00972995T ATE272115T1 (de) | 1999-11-01 | 2000-11-01 | Polypeptide die unnatürliche signalmotive enthalten |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1226244B1 (de) |
| JP (1) | JP2003512858A (de) |
| AT (1) | ATE272115T1 (de) |
| AU (1) | AU1155201A (de) |
| DE (1) | DE60012559T2 (de) |
| GB (1) | GB9925848D0 (de) |
| WO (1) | WO2001032709A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| US9181527B2 (en) | 2009-10-29 | 2015-11-10 | The Trustees Of Dartmouth College | T cell receptor-deficient T cell compositions |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| US12492376B2 (en) | 2009-10-29 | 2025-12-09 | The Trustees Of Dartmouth College | T-cell receptor-deficient T cell compositions |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| EP3505537A1 (de) | 2012-05-07 | 2019-07-03 | Trustees of Dartmouth College | Anti-b7-h6-antikörper, fusionsproteine und verfahren zur verwendung davon |
| EP2958942B1 (de) | 2013-02-20 | 2020-06-03 | Novartis AG | Effektives targeting primärer humaner leukämie mit durch den chimären anti-cd123-antigen-rezeptor veränderten t-zellen |
| ES2760023T3 (es) | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
| EP2970426B1 (de) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| RU2714902C2 (ru) | 2013-12-19 | 2020-02-20 | Новартис Аг | Химерные рецепторы антигена против мезотелина человека и их применение |
| EP3087101B1 (de) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulierbarer chimärer antigenrezeptor |
| EP4303229A3 (de) | 2014-01-21 | 2024-04-17 | Novartis AG | Verbessertes antigen mit car-t-zellfähigkeit durch co-einführung von co-stimulatorischen molekülen |
| ES2876263T3 (es) | 2014-04-07 | 2021-11-12 | Novartis Ag | Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19 |
| SG11201700416TA (en) | 2014-07-21 | 2017-02-27 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| EP3171882A1 (de) | 2014-07-21 | 2017-05-31 | Novartis AG | Behandlung von krebs mit einem chimären cll-1-antigenrezeptor |
| US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| US10174095B2 (en) | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
| DK3183268T3 (da) | 2014-08-19 | 2020-05-11 | Univ Pennsylvania | Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor |
| KR20210149228A (ko) | 2014-09-17 | 2021-12-08 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
| US10774388B2 (en) | 2014-10-08 | 2020-09-15 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
| US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| EP3286211A1 (de) | 2015-04-23 | 2018-02-28 | Novartis AG | Behandlung von krebs mit chimärem antigenrezeptor- und proteinkinase-a-blocker |
| SG10201912978PA (en) | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| CN108780084B (zh) | 2015-09-03 | 2022-07-22 | 诺华股份有限公司 | 预测细胞因子释放综合征的生物标志物 |
| CN108699557B (zh) | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| EP4643874A2 (de) | 2015-12-22 | 2025-11-05 | Novartis AG | Chimärer antigenrezeptor (car) gegen mesothelin und antikörper gegen pd-l1-inhibitor zur kombinierten verwendung in der antikrebstherapie |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| CA3039646A1 (en) | 2016-10-07 | 2018-04-12 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| EP3574005B1 (de) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28-zusammensetzungen und verfahren für chimäre antigenrezeptortherapie |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| CA3079407A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
| MY208825A (en) | 2018-06-13 | 2025-05-30 | Novartis Ag | Bcma chimeric antigen receptors and uses thereof |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994017095A1 (en) * | 1993-01-29 | 1994-08-04 | Ariad Pharmaceuticals, Inc. | Analogs of receptor tyrosine activation motifs and therapeutic uses thereof |
| GB9526131D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| GB9713473D0 (en) * | 1997-06-25 | 1997-09-03 | Celltech Therapeutics Ltd | Biological products |
| GB9908807D0 (en) * | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| EP1171596A1 (de) * | 1999-04-16 | 2002-01-16 | Celltech Therapeutics Limited | Synthetische transmembrankomponenten |
-
1999
- 1999-11-01 GB GBGB9925848.5A patent/GB9925848D0/en not_active Ceased
-
2000
- 2000-11-01 AT AT00972995T patent/ATE272115T1/de not_active IP Right Cessation
- 2000-11-01 WO PCT/GB2000/004183 patent/WO2001032709A2/en not_active Ceased
- 2000-11-01 DE DE60012559T patent/DE60012559T2/de not_active Expired - Fee Related
- 2000-11-01 EP EP00972995A patent/EP1226244B1/de not_active Expired - Lifetime
- 2000-11-01 JP JP2001535407A patent/JP2003512858A/ja active Pending
- 2000-11-01 AU AU11552/01A patent/AU1155201A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE60012559D1 (de) | 2004-09-02 |
| EP1226244B1 (de) | 2004-07-28 |
| DE60012559T2 (de) | 2005-08-18 |
| JP2003512858A (ja) | 2003-04-08 |
| WO2001032709A2 (en) | 2001-05-10 |
| EP1226244A2 (de) | 2002-07-31 |
| AU1155201A (en) | 2001-05-14 |
| WO2001032709A3 (en) | 2002-05-10 |
| GB9925848D0 (en) | 1999-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE272115T1 (de) | Polypeptide die unnatürliche signalmotive enthalten | |
| ES2145015T3 (es) | Proteasas especificas de ubiquitina. | |
| ATE318905T1 (de) | Homologe des tie-rezeptortyrosinekinase liganden | |
| DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
| EA199900355A1 (ru) | Теломераза обратная тринскриптаза | |
| DK1490386T3 (da) | Nyt polypeptid og nukleinsyrer kodende for dette | |
| IL152886A0 (en) | B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same | |
| ES2149149T1 (es) | Proteinas de fijacion de interleuquina-18, su preparacion y utilizacion. | |
| EP1067182A3 (de) | Sekretorische- oder Membranproteine | |
| WO2001049728A3 (en) | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS | |
| DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
| GEP20094629B (en) | Nogo receptor binding protein | |
| ATE327328T1 (de) | Adipozyten-spezifische protein homologe | |
| IL145689A0 (en) | Methods | |
| DK0990703T3 (da) | Nyt polypeptid, DNA, som koder herfor, samt anvendelse heraf | |
| MX9703364A (es) | Peptidos capaces de unirse al dominio sh3 de la proteina gap, secuencias nucleotidicas que codifican para estos peptidos, su preparacion y su uso. | |
| NO972063L (no) | Isolert BMP-reseptorkinaseprotein, DNA-sekvens, rekombinant ekspresjonsvektor samt vertscelle | |
| DE69504795D1 (de) | Methoden zur synthese und reinigung von peptiden | |
| NO922421D0 (no) | Collagenbindende protein, samt fremstilling derav | |
| TR200102655T2 (tr) | Dört L. infantum proteininin antijen belirleyicilerini kodlayan kimerik gen. | |
| BR9811907A (pt) | Proteìna de ligação de lactoferrina de neisseria | |
| WO2000059942A3 (en) | Human obesity protein binding protrein-2 homolog and uses thereof | |
| PT773999E (pt) | Receptor orfao or-1 pertencente a familia de receptores nucleares | |
| EP0592600A4 (de) | Protein-s polypeptide und deren verwendungen. | |
| RU2002103164A (ru) | Антибактериальный белок хламизин в, ген, кодирующий его, и экспрессирующая его система |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |